RecruitingNCT06546267

Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)

Efficacy of Advanced Radiotherapy (ART) in Prostate Cancer Patients With Early Stage, Advanced, Metastatic and Relapsed Disease (PROST-ART)

Sponsor

IRCCS San Raffaele

Enrollment

2,500 participants

Start Date

Feb 14, 2022

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer

Summary

This is a retrospective monoinstitutional study which analyses the results of advanced radiotherapy (IGRT, IMRT, SBRT, and PET-guided) performed for radical, adjuvant, or salvage purposes in patients with low, intermediate, high, and very high-risk prostate cancer, or with biochemical, lymph node, or oligometastatic recurrence treated between 2004 and 2024. Approved by Ethics Committee of IRCCS San Raffaele Hospital Approval Number: 187/INT/2021, 03/02/2022 Amendment approved by Ethics Committee 1, Lombardy Region Approval number CET Em. 194-2024, 22/05/2024

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 95 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting data from prostate cancer patients receiving advanced radiation therapy (IGRT, IMRT, or SBRT) to evaluate treatment outcomes and quality of life over time. **You may be eligible if...** - You have prostate cancer and are over 18 years old - You are receiving image-guided radiation therapy (IGRT), intensity-modulated radiation therapy (IMRT), or stereotactic body radiation therapy (SBRT) **You may NOT be eligible if...** - You have other active tumors - You are over 95 years old Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.